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Abstract: Despite numerous studies on women’s cardiac health throughout the past decade, the
number of female deaths caused by cardiovascular disease still rises and remains the leading cause
of death in women in most areas of the world. Novel studies have demonstrated that cardiovascular
disease, and more specifically coronary artery disease presentations in women, are different than
those in men. In addition, pathology and pathophysiology of the disease present significant
gender differences, which leads to difficulties concerning diagnosis, treatment and outcome of the
female population. The reason for this disparity is all steps for female cardiovascular disease
evaluation, treatment and prevention are not well elucidated; and an area for future research. This
review brings together the most recent studies published in the field of coronary artery disease
in women and points out new directions for future investigation on some of the important issues.
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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Objectives: Eligibility criteria for thrombolysis in ischemic stroke have been clearly deﬁ  ned. 
However, not all eligible patients beneﬁ  t from this treatment. This study aimed to assess the 
determinants for clinical outcome in consecutive, eligible patients with ischemic stroke treated 
with thrombolysis in a single-center study.
Methods: Consecutive patients with ischemic stroke were treated with tissue plasminogen 
activator (t-PA) following the established eligibility National Institute of Neurological Disorders 
and Stroke (NINDS) and European Stroke Initiative (EUSI) criteria. Risk factors including blood 
pressure and pre-treatment glycemia were properly managed. Death and disability at 3 months 
were the study outcomes. Disability was evaluated by the Rankin-scale. Favorable outcome 
was deﬁ  ned as 0–2 and adverse outcome as 3–6 including death.
Results: Seventy-eight patients were included in the study in a single stroke unit. The mean 
age was 70.9 ± 13.2 years (range 36–94). Follow-up at 3 months was completed in 73 patients. 
A favorable outcome was observed in 37 patients (50%) and adverse outcome in 36 (36%). 
Nine patients (12.3%) died within 3 months. The presence of an occluded carotid artery was a 
strong predictor for adverse outcome (p  0.0001). A low NIH Stroke Scale-Score (NIHSS) 
at admission was a associated with a favorable outcome, while history of diabetes mellitus led 
to an unfavorable outcome.
Conclusion: Among patients eligible for thrombolysis, many do not beneﬁ  t from this treat-
ment. These include patients with carotid occlusion and diabetes.
Keywords: thrombolysis, stroke, outcome, diabetes, carotid artery occlusion
Introduction
Stroke is the third leading cause of death after myocardial infarction and cancer, and is 
the leading cause of permanent disability in western countries (WHO 1999). Further-
more, it is the leading cause of disability-adjusted loss of independent life-years. Aside 
from the tragic consequences for the patients and their families, the socioeconomic 
impact of more or less disabled stroke survivors is evident, as stroke patients with 
permanent deﬁ  cits such as hemiparesis and aphasia will frequently not be able to live 
independently or pursue an occupation. The added indirect and direct cost estimates 
for a survived stroke vary between US$35,000 and 50,000 per year. In the face of our 
ageing population and the skewed population pyramid, the incidence and prevalence 
of stroke is expected to increase. Up to 85% of all strokes are of ischemic origin and 
are mostly caused by the blockage of a cerebral artery by a blood clot. Occlusion of 
a brain vessel leads to a critical reduction in cerebral perfusion and, within minutes, 
to ischemic infarction, with a central infarct core of irreversibly damaged brain 
tissue and an area of variable size of hypoperfused but still vital brain tissue (the 
ischemic penumbra), which can potentially be salvaged by rapid restoration of the 
blood ﬂ  ow. Therefore, the underlying rationale for the introduction and application 
of thrombolytic agents is the lysis of a thrombus and the subsequent re-establishment 
of cerebral blood ﬂ  ow by cerebrovascular recanalization (Schellinger et al 2001). Vascular Health and Risk Management 2006:2(4) 465–475
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the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
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Although approved by North American and, conditionally, 
by European authorities, thrombolysis is rarely used in the 
acute treatment of stroke. Fear of bleeding and scepticism 
about efﬁ  cacy are the main reasons of this underutilization. 
Indeed, difﬁ  culties in identifying those patients who may 
beneﬁ  t from thrombolysis treatment limit the widespread 
use of this therapy (Demchuk et al 2001). The short interval 
between symptom onset to treatment makes the decision 
even more difﬁ  cult. Other factors inﬂ  uencing the decision 
are direct and indirect costs. In addition to the crude cost of 
the thrombolytic agent, the cost of at least 24-hour patient 
monitoring should be considered as well as the necessity for 
specialized personnel in dedicated wards.
Based on the results of intervention studies, eligibil-
ity criteria for thrombolysis in ischemic stroke have been 
clearly deﬁ  ned. However, not all eligible patients beneﬁ  t 
from this treatment. The aim of this study was to assess the 
determinants for clinical outcome in consecutive eligible 
patients with ischemic stroke treated with thrombolysis at 
single institution.
Methods
Consecutive patients eligible for thrombolysis for ischemic 
stroke according to the NINDS and EUSI criteria were 
included in this study at the Stroke Unit, University of 
Perugia. (The Stroke Unit is the only department where 
intravenous thrombolysis treatment within three hours was 
performed, and serves an area of approximately 160,000 
inhabitants). The Italian emergency system 118 was orga-
nized to transport patients with acute stroke immediately 
to the Stroke Unit, because it was the referral hospital for 
thrombolysis treatment. All patients presented a NIH stroke 
scale-score (NIHSS) of 5–22, as foreseen by European stroke 
initiative (EUSI) guidelines (EUSI 2000, 2003) and National 
Institute of Neurological Disorders and Stroke (NINDS) 
criteria (NINDS 1995). These patients were divided into 
three groups according to clinical severity: NIHSS: 5–10 
(mild-moderate stroke), 11–15 (moderate-severe stroke), 
15 (severe stroke) (Golstein et al 1989).
Patients with a hypodensity larger than one third of the 
territory of middle cerebral artery (MCA) were excluded from 
treatment. Additionally, alberta stroke program early CT 
score (ASPECTS) was used to measure early infarct signs: 
patients with an ASPECTS-score 7 were also excluded 
from thrombolysis-treatment (Pexman et al 2001). Standard 
blood examinations including hematocrit and fasting blood 
glucose were measured at admission. Duplex-examination 
was performed on all patients. The diagnosis of internal 
carotid artery occlusion in the acute stage was done in case of 
absence of ﬂ  ow in the ICA at the level of carotid bifurcation. 
The Umbria Ethics Committee approved the protocol. The 
patients themselves or their relatives gave written informed 
consent for the treatment. This was the ﬁ  rst time in the Stroke 
Unit of Perugia that patients had been treated with throm-
bolysis. The physicians of the center had no experience in 
thrombolysis-treatment.
Neurological examinations were repeated: every 15 
minutes during infusion of t-PA, 1 hour after the end of 
infusion, after 24 hours and at discharge. Blood pressure 
was monitored every 15 minutes and measurements were 
repeated more frequently if systolic or diastolic pressures 
were 180 mm or 105 mm Hg, respectively. Antihy-
pertensive drugs, such as intravenous labetolol or urapidil, 
were administered as needed in case of hypertension. All 
patients underwent CT-scan 24 hours after thrombolysis, 
except in cases of neurological deterioration. In these cases 
CT-scan was performed to exclude any possible cerebral 
hemorrhagic complications. The hemorrhagic transforma-
tions were classiﬁ  ed according to the European Cooperative 
Acute Stroke Study I and II (ECASS and ECASS II) criteria 
(Hacke et al 1995, 1998).
Aspirin, heparin and warfarin were not administered 
for at least 24 hours following infusion. All protocol viola-
tions were registered and all extra-cranial hemorrhage were 
recorded Data were collected on vascular risk factors: age, 
sex, hypertension (blood pressure of 160/90 mmHg found 
at least twice before stroke or already under treatment with 
antihypertensive drugs), diabetes mellitus (glucose levels 
140 mg/dL preprandial from two examinations, glucose 
level 200 mg/dL postprandial, or HbA1c  8.5%), cigarette 
smoking (10 cigarettes per day or cessation 5 years 
earlier), hyperlipidemia (cholesterol concentration of 200 
mg/dL and/or triglyceride concentration 140 mg/dL the 
day after admission or if already under hypolipemiant ther-
apy), history of ischemic heart disease (proven myocardial 
infarction, existence of multiple lesions from thallium heart 
isotope screening, or evidence of coronary disease from 
coronary artery catheterization), arrhythmia, or vascular 
claudication, family history of stroke and/or heart disease, 
or previous transient ischemic attacks (TIAs).
An experienced neurologist reviewed the medical records 
of each patient and assigned stroke subtypes on the basis of 
the Trial of ORG 10172 in Acute Stroke Treatment-criteria 
(TOAST): atherosclerotic (large artery disease), cardioem-
bolic, lacunar (small artery disease), other determined etiolo-
gies and undetermined etiology (Adams 1993).Vascular Health and Risk Management 2006:2(4) 465–475
© 2006 Dove Medical Press Limited. All rights reserved
465
REVIEW
Leila Fernandes Araujo
Alexandre de Matos Soeiro
Juliano Lara Fernandes
Antônio Eduardo Pesaro
Carlos V Serrano Jr
Heart Institute (InCor), University
of São Paulo, School of Medicine,
Brazil
Correspondence: Carlos V Serrano Jr
Coronary Care Unit, Av. Dr. Enéas
Carvalho Aguiar, 44 – sala 12 – bloco 2,
São Paulo - SP - 05403-900, Brazil
Tel +55 11 3069 5058
Fax +55 11 3088 3809
Email carlos.serrano@incor.usp.br
Abstract: Despite numerous studies on women’s cardiac health throughout the past decade, the
number of female deaths caused by cardiovascular disease still rises and remains the leading cause
of death in women in most areas of the world. Novel studies have demonstrated that cardiovascular
disease, and more specifically coronary artery disease presentations in women, are different than
those in men. In addition, pathology and pathophysiology of the disease present significant
gender differences, which leads to difficulties concerning diagnosis, treatment and outcome of the
female population. The reason for this disparity is all steps for female cardiovascular disease
evaluation, treatment and prevention are not well elucidated; and an area for future research. This
review brings together the most recent studies published in the field of coronary artery disease
in women and points out new directions for future investigation on some of the important issues.
Keywords: coronary artery disease, women, risk factors, prevention, diagnosis, treatment.
Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
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than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
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Determinants of outcome in patients eligible for thrombolysis
Atherothrombotic strokes are characterised by presenta-
tion with ischemic stroke and 50% stenosis or occlusion of 
the supplying cerebral artery. Patients with aortic plaques of 
4 mm diameter or mobile aortic thrombi located before the 
ostium of the left subclavian artery, but in whom no signs of 
cardioembolic and other determined etiology of stroke were 
diagnosed at transoesophageal echocardiography, were also 
assumed to have atherothrombotic stroke. Cardioembolic 
strokes are characterized by presentation with an ischemic 
stroke and a potential cardiac source of embolism.
Lacunar strokes are characterized by presentation with 
one of the traditional clinical lacunar syndromes (pure 
motor hemiparesis, pure sensory syndrome, sensorimotor 
syndrome, ataxic hemiparesis, and dysarthria–clumsy hand 
syndrome), and (2) either normal brain computed tomogra-
phy/MRI or an appropriate subcortical or brain stem lesion 
of diameter 1.5 cm. Strokes with another determined etiol-
ogy refer to ischemic strokes caused by arterial dissection, 
ﬁ  bromuscular dysplasia, vasculitis, hematological disorder, 
migraine, and other rare forms of stroke. Strokes of unde-
termined etiology are ischemic strokes where the underlying 
cause during diagnostic work up remains undetermined, 
or where there are multiple possible causes of stroke or an 
incomplete evaluation.
Patients were followed up prospectively over the ﬁ  rst 3 
months after stroke during which the time of occurrence and 
the cause of death were recorded. Death was categorized into 
neurological causes: oedema, herniation, status epilepticus, 
recurrence of stroke, and non-neurological: myocardial 
infarction, pneumonia, sudden death, other cardiovascular 
diseases, cancer, pulmonary embolism, gastrointestinal 
hemorrhage and other causes. At follow-up after 3 months, 
dependency was assessed with the modiﬁ  ed Rankin Scale 
(mRS) (Van Swieten 1988). Favorable outcome was deﬁ  ned 
as 0–2 and adverse outcome as 3–6 including death (Hacke 
et al 1999).
Statistical analysis
Crude association between each of the categorical baseline 
variables and adverse outcome at three months was assessed 
by preliminary cross-tabulations with the χ2 test or Fisher’s 
exact test with Yate’s correction when appropriate. Multiple 
logistic regression analysis was used to identify indepen-
dent predictors for outcome at 3 months. The independent 
variables included in this analysis were selected from the 
bivariate analysis with a 0.25 level as a screening criterion 
for selection of candidate variables. Assumptions underlying 
the use of such a regression model were tested according to 
recommended procedures (Leys 1989). Data were analyzed 
with the SPSS/PC – Win Package.
Results
From December 2001 to July 2004, 78 stroke patients were 
treated with thrombolysis. The mean age was 70.9 ± 13.2 
years (range 36–94). Distribution of patient risk factors is 
shown in Table 1. Mean time from stroke onset to treatment 
was 160 minutes, while mean time from stroke to hospital 
arrival was 86 minutes.
Follow-up at three months was completed in 73 patients. 
A favorable outcome was observed in 37 patients (50.7%) 
and adverse outcome in 36 patients (49.3%) (Table 1). Nine 
patients (12.3%) died within three months: 2 malignant 
MCA infarcts, 3 internistic complications (pleuritis, 
pulmonary embolism), 2 sudden deaths, 2 acute myocardial 
infarctions, 1 controlateral stroke recurrence and 1 cerebral 
hemorrhage occurring 2 months after ﬁ  brinolytic treatment 
in a patient with a probable amiloid angiopathy. The baseline 
median NIHSS value was 10 (range 5–22): 38 patients 
(52%) presented a NIHSS of 5–10, 20 (27%) a NIHSS of 
11–15 and 15 (21%) (15). A high NIHSS-score before 
thrombolytic treatment was associated with increased risk 
of adverse outcome (Table 2), while a low score seemed to 
be associated with a favorable outcome. In the multivariate 
analysis only a low NIHSS-score seemed to be protective 
against adverse outcome. All patients underwent Duplex 
examination before thrombolysis treatment. Four patients 
underwent MRI-angiography, 5 CT-angiography within 3 
Table 1 Vascular risk factors and outcome in patients receiving 
thrombolysis for ischemic stroke (univariate analysis)
Vascular risk-  Overall   Favorable  Adverse  P value
factors number/%  outcome  outcome
Age (mean)  70.03 ± 13.05 67.11 ± 14.39 74.40 ± 10.03 p = 0.01
Male  sex  44/60.2  22/59.9 22/61.1 p = ns
Hyperlipidemia  27/36.9  13/35.1 14/37.8 p = ns
Previous stroke  16/21.9  6/16.2  10/27.7  p = ns
Atrial ﬁ   brillation  21/28.7  11/29.7 10/27.7 p = ns
Peripheral  artery  5/6.8  3/8.1 2/5.5 p = ns
disease
Hypertension  56/76.7  30/83.3 26/70.2 p = ns
Diabetes mellitus  14/19.1  4/11.1  10/27.0  p = 0.081
Coronary  disease  6/8.2  3/8.1 3/8.1 p = ns
Previous  aspirin  33/45.2  14/38.8 19/52.7 p = ns
use
Carotid artery  11/15.0  0/0  11/100  p < 0.0001
occlusion
Smoking  14/19.1 9/24.3 5/13.8 p = ns
Cerebral   6/8.2  3/8.1 3/8.1 p = ns
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days of stroke onset while 2 patients died due to malignant 
MCA-infarct before further neuroradiological examinations 
could be performed. No patient presented recanalization of 
carotid artery and the two patients who died of malignant 
MCA-infarct were considered as not recanalized as well. No 
patient had occlusion due to cervical artery dissection. Eleven 
patients (14%) had carotid artery occlusions. Seven of these 
patients (63.7%) died or 4 (36.3%) were disabled at 3 months. 
The association between carotid artery occlusion and adverse 
outcome was statistically signiﬁ  cant (p = 0.0001) in the 
univariate analysis. Multivariate analysis was not performed 
for carotid artery occlusion, because no patient with carotid 
artery occlusion had a favorable outcome. The presence of 
carotid artery occlusion was not statistically associated with 
NIHSS 15 (p = 0.06), while only two patients with a NIHSS 
5–10 had a carotid artery occlusion (p = 0.02).
Age was signiﬁ  cantly associated with stroke outcome in 
the univariate analysis, but not in the multivariate analysis. 
In the univariate analysis for diabetes there was only a 
tendency to be statistically signiﬁ  cant (p = 0.081), while in 
the multivariate analysis diabetes was an independent risk 
factor for outcome (Table 3). Mean glycemia at admission 
was 131 ± 34 mg/dL and only 1 patient had hyperglycemia 
(250 mg/dL). The glucose levels at admission did not 
inﬂ  uence the outcome at three months in the multivariate 
analysis. Mean diastolic blood pressure was 83 ± 12 mm Hg 
and mean systolic blood pressure was 156 ± 24 mm Hg. 
The median ASPECT-score was 10 (65 of 78 patients had a 
normal CT-scan at admission). Aspirin pretreatment was not 
statistically associated with adverse outcome (Table. 2) The 
stroke subtypes were distributed as following: 17 (21.7%) 
patients with large vessel disease, 30 (38.4%) with cardio-
embolic stroke, 13 (16.6%) with lacunar stroke, 3 (3.8%) 
other causes and 15 (19.2%) with undetermined stroke. 
None of the stroke subtypes was statistically associated with 
adverse outcome.
Cerebral hemorrhagic complications were observed in 6 
patients: 3 symptomatic hemorrhages (RS = 2 at 3 months) 
and 3 asymptomatic cerebral hemorrhages. Cerebral hem-
orrhages were observed in the territory of cerebral anterior 
artery (2) and posterior cerebral artery (1). Extracranial 
hemorrhages had been observed in 10 patients: ﬁ  ve had 
hematuria and ﬁ  ve had subgingival hemorrhage.
Discussion
In our study 73 completed the 3-month follow-up and 50.7% 
had a favorable outcome. These results are in keeping with 
those from NINDS as well as post-marketing studies such as 
Canadian activase for stroke effectiveness study (CASES), 
standard treatment with alteplase to reverse stroke (STARS) 
and Colonia (Hill et al 2002; Albers et al 2000; Grond 
et al 1998). Additionally, the observed rate of hemorrhagic 
complications was not higher than in randomized controlled 
trials (RCT) (NINDS 1995; Hacke et al 1995, 1998; Clark 
et al 1999).
In our study population we identiﬁ  ed sub-groups of 
patients who did not beneﬁ  t from t-PA. All patients with 
carotid occlusion had an adverse outcome, the majority of 
patients died, while the remaining patients were disabled at 
follow-up. Trouillas et al (1998) observed that patients with 
atheromatous proximal carotid occlusion treated with throm-
bolysis within 7 hours had an adverse outcome (p = 0.02). 
These results should be interpreted with caution, because in 
this study patients were treated in a larger time frame. Indeed, 
in a recent meta-analysis of thrombolysis-trials Hacke et al 
showed that the beneﬁ  t of thrombolysis-therapy decreases 
with the prolonging of time-frame and the net beneﬁ  t was 
only evident until the fourth hour after onset (Hacke et al 
2004).
Rudolf et al (2000) evaluated both 9 carotid artery occlu-
sions due to atherothrombotic disease and 6 due to cervical 
artery dissection. In this study 3 out of 15 patients showed 
an excellent clinical outcome, so that the authors concluded 
that patients with carotid artery occlusion should not be 
excluded a priori from thrombolysis therapy (Rudolf et al 
2000). Even so, prognosis of carotid artery occlusion due 
to cervical artery dissection is more favorable compared to 
atherothrombotic occlusion (Arnold et al 2001) so that these 
two patient groups could not be put together.
A recent study compared the outcome of patients with 
carotid artery occlusion to those with MCA occlusion 
(Linfante et al 2002) and found a higher recanalization rate in 
Table 2 The NIHSS of thrombolysis treated patients and 
statistical signiﬁ  cance for outcome in univariate analysis
NIHSS-score   Total number/  Favorable  Adverse  P value
 % outcome  outcome
0−10   38/52.0  27/71.0  11/28.9  p < 0.0001
11−15 20/27.3 6/30.0  14/70.0  p = 0.038
>15 15/20.5  4/26.6  11/73.3  p = 0.046
Table 3 Multivariate analysis of determining factors of outcome
  OR  95% CI  P value
NIHSS 0–10  0.19  0.05–0.41  p = 0.006
Diabetes 12.3  1.2–117.4  p = 0.02Vascular Health and Risk Management 2006:2(4) 465–475
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Abstract: Despite numerous studies on women’s cardiac health throughout the past decade, the
number of female deaths caused by cardiovascular disease still rises and remains the leading cause
of death in women in most areas of the world. Novel studies have demonstrated that cardiovascular
disease, and more specifically coronary artery disease presentations in women, are different than
those in men. In addition, pathology and pathophysiology of the disease present significant
gender differences, which leads to difficulties concerning diagnosis, treatment and outcome of the
female population. The reason for this disparity is all steps for female cardiovascular disease
evaluation, treatment and prevention are not well elucidated; and an area for future research. This
review brings together the most recent studies published in the field of coronary artery disease
in women and points out new directions for future investigation on some of the important issues.
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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Determinants of outcome in patients eligible for thrombolysis
patients with MCA-occlusion, although the effect on clini-
cal outcome remains unclear. Probably MCA occlusion is 
more often embolic while carotid artery occlusion is more 
often atherosclerotic and complicated by embolic occlusion 
(Del Zoppo 1992; Mori 1992). Nevertheless, thrombolytic 
therapy could increase collateral ﬂ  ow leading to improved 
brain perfusion.
The limit of all the above mentioned studies including 
ours is the absence of an untreated control group. However, it 
is well known from RCT on thrombolysis that the main cause 
of death in the placebo group is MCA infarction. This leads to 
subsequent transtentorial herniation due to space-occupying 
brain oedema (Hacke et al 1996) which is likely in patients 
with a total anterior cerebral infarct following carotid artery 
occlusion (Hacke et al 1996). Whether a Duplex-examination 
should be performed in all patients before thrombolysis 
and those with carotid occlusion excluded remains to be 
established in properly designed clinical trials.
In our study, patient age did not seem to be an indepen-
dent risk factor for adverse outcome, even if patients with 
adverse outcome were on average seven years older than 
patients with favorable outcome. Tanne et al (2000) in a recent 
study, compared the outcome of 30  80 year-old patients to 
younger patients. No signiﬁ  cant difference in outcome was 
found, while Mouradian et al showed in another study that 
older patients presenting with more severe baseline stroke 
were much less likely to beneﬁ  t from iv rt-PA as compared 
with their younger counterparts (Mouradian 2005). Data from 
the CASES-study showed that in carefully selected elderly 
patients, the use of intravenous tPA was not found to be 
associated with an increased risk of symptomatic intracerebral 
hemorrhage. The differences in outcome were age-related 
and had the clinical characteristics of outcome in the elderly 
population (Sylaja 2006). However, Heuschmann et al found a 
higher in-hospital mortality with for each 10 years of increas-
ing age (Heuschmann et al 2004). The possibility that elderly 
patients could beneﬁ  t from thrombolysis is clinically relevant 
since age is one of the major determining factors of disability 
and death in stroke patients (Weimar et al 2002; Henon et al 
1995). Indeed mean life-expectancy in Western countries 
is prolonged, increasing the prevalence of cerebrovascular 
disease (Sarti et al 2002).
Consistent with other studies, milder baseline stroke 
severity and no history of diabetes mellitus were identiﬁ  ed 
as independent predictors of favorable outcome in patients 
treated with tPA (Demchuk et al 2001). In our study the 
baseline NIHSS was 10, which could explain partially the 
good outcome of the patients.
Data from NINDS-study and from a recent Canadian 
open-label study showed that glycemia and uncontrolled 
blood pressure levels are markers of adverse outcome in 
patients treated with thrombolysis (Bruno et al 2002; Saposnik 
et al 2004; Demchuk et al 2001). Here, only one patient had 
glycemia higher than 200 mg/dL before treatment while no 
patient presented uncontrolled hyperglycemia. Additionally, 
blood pressure was monitored before and during thrombolytic 
treatment and in no patient thrombolysis was started if blood 
pressure was higher than indicated by protocol guidelines. In 
these cases, patients were treated with infusion of urapidil 
with an excellent control of blood pressure levels. Probably 
due to the low number of patients, the different variables did 
not reach statistical relevance.
Clinical studies showed that thrombolysis is beneﬁ  cial 
in patients with acute stroke. However, doubts remain on 
which patients could most beneﬁ  t from this therapy. Even 
in a limited number of patients we identiﬁ  ed factors that 
were predictive of favorable or adverse outcome. Among 
the former, there was a milder baseline stroke severity and 
among the latter a presence of carotid artery occlusion and 
diabetes; the more that these data will be archived, the larger 
the beneﬁ  t of thrombolysis will be in stroke patients.
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